Canada: Canadian Patent Law: 2014 Year In Review

This article summarizes noteworthy Canadian patent law decisions and developments from 2014.

1. Court of Appeal addresses patent utility in Celebrex

Canadian Courts have continued to address allegations that patents are invalid because they lack utility. A notable 2014 Court of Appeal decision in this regard is Celebrex (Apotex Inc v. Pfizer Canada Inc, 2014 FCA 250).

In Celebrex, the Court of Appeal addressed the "promise of the patent" doctrine and, in short, found that an inventor who explicitly promises a specific result will be held to that promise for establishing utility. 

Section 2 of Canada's Patent Act requires, among other things, that an invention be "useful", i.e., that it possess utility.  Courts have long held that it is not difficult to meet the requirement of utility.  In this regard, an inventor need not expressly set out the utility of the invention in the patent.  Rather, it is merely required that, where the inventor is called upon to prove the utility of the invention, utility can be shown to be demonstrated or soundly predicted as of the patent's filing date.  The threshold that must be proven to establish utility is generally quite low, described as being no more than a "scintilla of utility".

Notwithstanding the traditionally low threshold for utility, the Court of Appeal stated that the "promise doctrine represents an exception to the above minimum statutory requirements". In this regard, "[t]hough an inventor need not describe any particular utility for the invention, an inventor who explicitly promises a specific result will be held to that promise when called upon to prove utility... That the invention may well have satisfied the scintilla threshold is of no assistance in establishing utility where a promise, if it be made, cannot be met".

At issue in Celebrex was whether certain statements in the patent's disclosure rose to the level of explicit promises.  Ultimately, the Court of Appeal upheld the lower Court's findings that there were no explicit promises.  In particular, the patent did not contain an explicit and unequivocal promise regarding side effects or treatment in humans, but rather only a possibility of reduced side effects and claims that spoke only of the treatment of "subjects".  At most, reduced side effects were understood to be a goal or advantage, but not a promise that would implicate the promise doctrine.

Celebrex is consistent with the Court of Appeal's findings in Plavix (sanofi-aventis v. Apotex Inc, 2013 FCA 186) regarding the promise doctrine.  The Supreme Court of Canada was set to hear argument with respect to an appeal from the Court of Appeal's decision in Plavix in November 2014; however, the appeal to the Supreme Court was discontinued just prior to the hearing.  As a result of such discontinuance, the Supreme Court did not have an opportunity to provide any guidance regarding the requirement for utility.

2. Dow v. NOVA: patent covering ethylene polymer compositions found valid and infringed

In Dow Chemical Company v. NOVA Chemicals Corporation, 2014 FC 844, the Federal Court made a number of findings of general relevance to patent infringement actions in arriving at its conclusion that Dow's patent covering ethylene polymer compositions was valid and infringed.  These findings include the following:

  • Promised utility: consistent with the Court of Appeal in Celebrex, the Court held that for a statement in a patent specification to rise to the level of a promise, there must be a clear an unequivocal statement that it is part of the promised utility of the invention. Otherwise, the statement should not be taken as anything more than a mere statement of advantage. Moreover, one should particularly look to the claims of the patent for any elevated promise or claimed utility;
  • Test for anticipation: consistent with other patent cases addressing the issue of anticipation, the Court held that a prior art reference must disclose subject matter that if performed would "necessarily result in infringement of that patent."  In this case, it was possible to perform subject matter disclosed in a prior art reference and not arrive at the claimed invention. As such, the reference was not anticipatory;
  • Test for obviousness: it is well-accepted that the test for obviousness is largely concerned with how a skilled worker would have acted in the light of the prior art. In this case, the Court adopted reasoning from earlier case law regarding where the line is drawn between publicly-available documents and information that forms part of the skilled person's common general knowledge: "it is not sufficient to prove common general knowledge that a particular disclosure is made in an article, or series of articles, in a scientific journal, no matter how wide the circulation of that journal may be, in the absence of any evidence that the disclosure is accepted generally by those who are engaged in the art to which the disclosure relates... Such a piece of knowledge only becomes general knowledge when it is generally known and accepted without question by the bulk of those who are engaged in the particular art;" and
  • Legal tests applied by expert witnesses: the Court found that the defendant's expert applied the wrong standard for assessing obviousness when the expert acknowledged that the skilled person – who is by definition uninventive and unimaginative – would have had an imagination. This finding is a reminder to litigants of the importance of ensuring expert witnesses understand and properly apply legal tests when rendering opinions and being the subject of examination at trial.

3. Noteworthy decisions regarding pharmaceutical patent cases

In 2014, there were several noteworthy decisions dealing specifically with pharmaceutical patent cases:

  1. Biologic patent infringement action: in Abbvie Corporation v. Janssen Inc., 2014 FC 55, the Federal Court found Abbvie's patent related to human antibodies to be valid and infringed.  It was the first biologics patent decision of the Court in fifteen years.  Notwithstanding that Abbvie itself did not practice its patented invention, the Court in 2014 FC 489 granted Abbvie a permanent injunction prohibiting Janssen from engaging in certain activities. Eventually, the decisions at the trial level were considered by the Court of Appeal and set aside such that a new trial was ordered.  See 2014 FCA 242 and 2014 FCA 241 in this regard. The basis for setting aside the trial-level decisions was that the trial judge erred in not allowing Janssen to rely upon certain prior art alleged for the first time just prior to trial. In particular, the Court of Appeal held that it was in the interests of justice to have all relevant prior art before the trial judge even if it meant increased delays and costs in having the matter decided. Following these decisions, the matter settled;
  1. Punitive damages are not available to generics in section 8 damages cases: in Teva Canada Limited v. Pfizer Canada Inc, 2014 FCA 138, the Court of Appeal considered whether punitive damages should be available in the context of section 8 damages cases, which are cases designed to compensate generic companies for losses sustained due to delayed market entry resulting from the statutory stay that applies when an innovator applies to the Court to prevent such market entry. The Court of Appeal ultimately held that claims for punitive or exemplary damages are not available in a section 8 proceeding. That is, generics are limited to claims for compensatory damages, not other monetary claims such as punitive damages or disgorgement of profits as had been claimed in earlier cases;
  1. Law is "unsettled" with respect to disclosure requirement for cases involving sound prediction of utility: in AstraZeneca Canada v. Apotex Inc, 2014 FC 638, the Court commented on the doctrine of sound prediction of utility. Since the Supreme Court's decision in the AZT case in 2002 (see 2002 SCC 77), Courts have been requiring that patents include a heightened degree of disclosure in cases where utility was not demonstrated, but rather soundly predicted.  In this case, the Court stated that the requirement for proper disclosure of utility is limited to the context of 'new use' patents. That is, it is not a requirement for all cases of sound prediction. The rationale in this regard is that in a new use case, there may be an enhanced disclosure requirement because utility is the only thing being offered in exchange for the patent monopoly; and
  1. Experimental use not enough for proving anticipation: in Bayer Inc v Apotex Inc, 2014 FC 436, the generic argued that clinical trials conducted pre-patent filing constituted anticipatory disclosures. The Court disagreed. In particular, the Court found that experimental use in order to bring the invention to perfection does not constitute public use. While there was a theoretical possibility that a tablet could have been taken and reverse engineered, the evidence demonstrated that the patentee had taken steps to preserve the confidentiality of relevant information and to have tablets not used in the trials returned to it.

4. Changes coming to Canada's Patent Act and Industrial Design Act

Notable changes are coming to Canada's Patent Act, including the following:

  • Reinstatement of abandoned applications: reinstating abandoned Canadian applications is about to become more complex for applicants. Under the current regime, applicants can easily reinstate abandoned applications within 12 months of abandonment by making a request, paying a fee and completing whatever step was not completed at the time of abandonment. Under the new regime, applicants will be additionally required to provide "reasons" for why the applicant failed to take steps to avoid the abandonment. The Patent Office will then evaluate whether the applicant exercised "due care" notwithstanding the abandonment. As a result of these changes, applicants will need to act with much greater care when it comes to maintaining and prudently prosecuting applications;
  • Reference to priority application: Canadian practice prohibits "incorporation by reference" statements in patent disclosures. However, under amendments to the Patent Act, applicants will now be permitted to reference a priority application. By including such a reference, an applicant will be allowed to add subject matter to an application that otherwise may have been considered to be impermissibly new;
  • Notices from the Patent Office: where a deadline for a fee payment has been missed, the Patent Office will now notify an applicant of the missed payment, and payment (including a late fee) must be made within 2 months of the notice or 6 months of the original deadline date (whichever is later); and
  • Requests for priority: where a request for priority based on an earlier priority application was unintentionally not made at the time of filing, an applicant will have until 14 months from the date of the priority application to make the request for priority.

More detail regarding the above and other changes is available here.

In addition, Canada's Industrial Design Act will be subject to a number of changes, including changes related to a new "novelty" requirement, new priority claims and term of protection, all of which are discussed in more detail here.

The above-noted changes to the Patent Act and Industrial Design Act have been announced, but are not yet in force.

5. New guidelines issued for experimental testing in patent actions

In 2014, the Federal Court issued a Notice to the Profession requiring a litigant to give an opposing party notice of experimental testing to be conducted for the purpose of litigation in a patent infringement (or impeachment) action. The notice must include:

  • the facts to be proven by such testing;
  • the nature of the experimental procedure to be performed;
  • when and where the adverse parties' counsel and representative(s) can attend to watch the experiment(s); and
  • when and in what format the data and test results from such experiment(s) will be shared with the adverse parties.

This notice must be provided two months before the scheduled service of the expert report(s) in chief. Any disputes about the required notice may be resolved at a case management conference. Failure to abide by the notice requirements precludes a party from adducing experimental testing evidence, subject to leave of the Court.

Further discussion regarding this Notice, including background related thereto and questions that it raises, is available here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions